BenzingaSeptember 2, 2026 at 3:40 AM NY2 days ago
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill1 hour ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill2 hours ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo3 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo3 hours ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo3 hours ago